Dakota Wealth Management Sells 2,170 Shares of Axon Enterprise, Inc (NASDAQ:AXON)

Dakota Wealth Management trimmed its stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 46.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,464 shares of the biotechnology company's stock after selling 2,170 shares during the quarter. Dakota Wealth Management's holdings in Axon Enterprise were worth $1,296,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. TimesSquare Capital Management LLC grew its holdings in Axon Enterprise by 118.6% in the first quarter. TimesSquare Capital Management LLC now owns 122,250 shares of the biotechnology company's stock worth $64,297,000 after purchasing an additional 66,320 shares during the period. Asahi Life Asset Management CO. LTD. acquired a new stake in Axon Enterprise in the first quarter worth $413,000. Apollon Wealth Management LLC lifted its stake in shares of Axon Enterprise by 63.0% in the first quarter. Apollon Wealth Management LLC now owns 2,018 shares of the biotechnology company's stock valued at $1,061,000 after buying an additional 780 shares in the last quarter. Sigma Planning Corp lifted its stake in shares of Axon Enterprise by 50.3% in the first quarter. Sigma Planning Corp now owns 2,472 shares of the biotechnology company's stock valued at $1,300,000 after buying an additional 827 shares in the last quarter. Finally, Signaturefd LLC lifted its stake in shares of Axon Enterprise by 10.4% in the first quarter. Signaturefd LLC now owns 838 shares of the biotechnology company's stock valued at $441,000 after buying an additional 79 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, President Joshua Isner sold 905 shares of the business's stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $776.39, for a total value of $702,632.95. Following the sale, the president owned 268,735 shares of the company's stock, valued at $208,643,166.65. The trade was a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 1,300 shares of the business's stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $738.84, for a total transaction of $960,492.00. Following the completion of the sale, the director directly owned 4,829 shares in the company, valued at approximately $3,567,858.36. This trade represents a 21.21% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,642 shares of company stock worth $30,500,428 in the last ninety days. 4.40% of the stock is owned by corporate insiders.

Axon Enterprise Stock Up 0.4%

AXON stock traded up $2.84 during trading on Friday, reaching $748.70. The stock had a trading volume of 109,403 shares, compared to its average volume of 697,410. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $58.29 billion, a price-to-earnings ratio of 180.85, a P/E/G ratio of 85.50 and a beta of 1.29. Axon Enterprise, Inc has a one year low of $279.02 and a one year high of $830.21. The company's 50 day moving average is $762.11 and its two-hundred day moving average is $644.50.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The company had revenue of $603.63 million for the quarter, compared to analysts' expectations of $585.67 million. During the same quarter in the previous year, the firm posted $1.15 EPS. Axon Enterprise's revenue was up 31.3% on a year-over-year basis. Equities research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analyst Ratings Changes

AXON has been the topic of a number of recent research reports. The Goldman Sachs Group raised their price objective on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. Bank of America raised their price objective on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a research note on Wednesday, June 4th. Barclays raised their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. Morgan Stanley set a $885.00 price objective on shares of Axon Enterprise and gave the company an "overweight" rating in a research note on Friday, July 11th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an "overweight" rating in a research note on Thursday. One analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $763.75.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.